• About
    • About Sutro
    • Patient Resources
    • Collaborations
    • Corporate Presentation
  • Leadership
    • Leadership Team
    • Board of Directors
    • Scientific Advisory Board
    • Clinical Advisory Board
  • Technology
    • XpressCF® and XpressCF+™ Platforms
    • Antibody-Drug Conjugates and IADCs
    • Bispecific and Engineered Antibodies
    • cGMP Facility
  • Investors
    • Company Presentation
    • Stock
    • Financials
    • Governance
    • Contact IR
    • Email Alerts
  • Pipeline
  • News
    • News Releases
    • Clinical / Scientific Presentation and Publication Highlights
    • Events
    • Events Audio Replays
  • Careers and Culture
    • The Way We Work
    • Join Our Team
    • Diversity, Equity, Inclusion and Belonging
      • DEIB Newsletter
    • Internships
    • Sutroites
    • Volunteer Opportunities
  • Contact Us

Changing the future of Oncology.

12th Annual World ADC London 2022 – Presentations

Mar 30, 2022

World ADC 2022 presentation titled, “A New Molecular Class to target Tumor Immunity by both disrupting the tumor and enabling the immune system” presented by  Trevor Hallam, Ph.D., President of Scientific and Chief Scientific Officer.

Download Here

World ADC 2022 presentation titled, “Targeting FolRα in Gynecologic Cancers & other Solid Tumours with the Novel Antibody-Drug Conjugate, STRO-002” presented by Arturo Molina, MD, MS, Chief Medical Officer.

Download Here

Sutro Biopharma

111 Oyster Point Blvd
South San Francisco, CA 94080
Phone: 650-881-6500
Fax: 650-553-9659

Google Map

Tweets by @sutrobio

Contact Us

General Inquires:
general@sutrobio.com
Business Inquires:
busdev@sutrobio.com
Investor Relations Inquires:
IR@sutrobio.com
Careers:
jobs@sutrobio.com

© 2022 Sutro Biopharma, Inc. – Privacy Policy
  • Follow
  • Follow
  • Follow